Evaluation of the risk of nitrosamine impurities

White papers - 6 May 2020

BlueReg Group White papers Evaluation of the risk of nitrosamine impurities

Evaluation of the risk of nitrosamine impurities

“During the summer 2018, authorities become aware of the presence of some nitrosamines in API – (Valsartan – presence of N- nitrosodimethylamine (NDMA) – other sartans – presence of N-nitrosodiethylamine NDEA).   These nitrosamines were already known as probable carcinogenic compounds but their presence in the sartans was not then identified.”

 

To read the whole document, please download the white paper.

Did you like this article? Share on social networks:


    By sending this form, I agree that my personal data will be saved and processed according to data protection regulations and will be used only for commercial and marketing purposes only.

    Learn more


    BlueReg undertakes to comply with the regulations in force applicable to the processing of personal data and, in particular, Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 applicable as from 25 May 2018 (hereinafter, "the General Data Protection Regulations" or GPDR) and the national laws resulting therefrom.
    Any inquiries, correction or declaration of event related to personal data processed should be sent to: GDPR data request

    Thank you for your reply

    You can download the file below

    Download

    Contact our experts today

    Composed of proven experts from the pharmaceutical industry, our team is ready to answer to your needs in any area of product development, commercialisation and early access programs, and life cycle management

    Make an enquiry